{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T09:34:07Z","timestamp":1777023247360,"version":"3.51.4"},"reference-count":32,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Objective: To determine whether asymptomatic bacteriuria (ABU) prior to Bacillus Calmette-Gu\u00e9rin (BCG) immunotherapy has an impact on the oncological results and overall tolerability of BCG treatment in patients with non-muscle-invasive bladder cancer (NMIBC).\nMaterials and methods: We analyzed retrospectively all patients who received \u2265\u20091 BCG instillations as treatment of NMIBC in Helsinki University Hospital and Turku University Hospital during 2009\u20132018. Patients submitted urine specimen 1\u20137 days prior to the initiation of BCG therapy. ABU was classified as having any positive urine culture but no dysuria or fever. Our primary endpoints were 5-yr recurrence-free survival and progression-free survival. Discontinuation rate of BCG therapy was a secondary endpoint.\nResults: We identified 795 patients, of whom 154 (19%) had ABU prior to the first BCG instillation. The 5-yr recurrence-free survival rates in the uninfected and bacteriuric groups were 63% (95% confidence interval [CI]: 59\u201367%) vs. 69% (95% CI: 62\u201378%), respectively (hazard ratio [HR] 0.83, 95% CI 0.60\u20131.14). The 5-yr progression-free survival rates were 88% (95% CI: 86\u201390%) vs. 89% (95% CI: 84\u201394%), respectively (HR 0.86, 95% CI 0.50\u20131.49). The 3-yr discontinuation-free survival rates were 51% (95% CI: 47\u201354%) vs. 51% (95% CI: 44\u201360%), respectively (HR 0.98, 95% CI 0.75\u20131.28).\nConclusion: ABU did not significantly affect BCG immunotherapy outcomes. Intravesical BCG during ABU is safe, with similar discontinuation rates, indicating very similar treatment tolerability.<\/jats:p>","DOI":"10.2340\/sju.v61.45539","type":"journal-article","created":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:34:09Z","timestamp":1777019649000},"page":"148-155","source":"Crossref","is-referenced-by-count":0,"title":["Impact of asymptomatic bacteriuria on the outcomes and tolerability of Bacillus Calmette\u2013Gu\u00e9rin immunotherapy"],"prefix":"10.2340","volume":"61","author":[{"given":"Antti","family":"Nummi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pertti","family":"Nurminen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olli","family":"Kesti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikael","family":"H\u00f6german","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto","family":"Ettala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter J.","family":"Bostr\u00f6m","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Kaipia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jukka","family":"Sairanen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riikka","family":"J\u00e4rvinen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1183","published-online":{"date-parts":[[2026,4,24]]},"reference":[{"key":"152343","doi-asserted-by":"crossref","unstructured":"Babjuk M, B\u00f6hle A, Burger M, et al. EAU guidelines on non\u2013muscle-\u00adinvasive urothelial carcinoma of the bladder: update 2016. Eur Urol. 2017;71(3):447\u2013461.","DOI":"10.1016\/j.eururo.2016.05.041"},{"key":"152344","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2016.05.041","DOI":"10.1016\/j.eururo.2016.05.041"},{"key":"152345","doi-asserted-by":"crossref","unstructured":"Shelley MD, Kynaston H, Court J, et al. A systematic review of intravesical bacillus Calmette-Gu\u00e9rin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer. BJU Int. 2001;88(3):209\u2013216.","DOI":"10.1046\/j.1464-410x.2001.02306.x"},{"key":"152346","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1046\/j.1464-410x.2001.02306.x","DOI":"10.1046\/j.1464-410x.2001.02306.x"},{"key":"152347","doi-asserted-by":"crossref","unstructured":"Song J, Abraham SN. Innate and adaptive immune responses in the urinary tract. Eur J Clin Investig. 2008;38(s2):21\u201328.","DOI":"10.1111\/j.1365-2362.2008.02005.x"},{"key":"152348","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/j.1365-2362.2008.02005.x","DOI":"10.1111\/j.1365-2362.2008.02005.x"},{"key":"152349","doi-asserted-by":"crossref","unstructured":"Ingersoll MA, Albert ML. From infection to immunotherapy: host immune responses to bacteria at the bladder mucosa. Mucosal Immunol. 2013;6(6):1041\u20131053.","DOI":"10.1038\/mi.2013.72"},{"key":"152350","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1038\/mi.2013.72","DOI":"10.1038\/mi.2013.72"},{"key":"152351","doi-asserted-by":"crossref","unstructured":"Morales A, Eidinger D, Bruce AW. Intracavitary Bacillus Calmette-guerin inthe treatment of superficial bladder tumors. J Urol. 1976;116(2):180\u2013182.","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"152352","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0022-5347(17)58737-6","DOI":"10.1016\/S0022-5347(17)58737-6"},{"key":"152353","doi-asserted-by":"crossref","unstructured":"Hern\u00e1ndez JG, Sund\u00e9n F, Connolly J, et al. Genetic control of the variable innate immune response to asymptomatic bacteriuria. PLoS One. 2011;6(11):e28289.","DOI":"10.1371\/journal.pone.0028289"},{"key":"152354","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1371\/journal.pone.0028289","DOI":"10.1371\/journal.pone.0028289"},{"key":"152355","doi-asserted-by":"crossref","unstructured":"Herr H. Does asymptomatic bacteriuria affect the response to intravesical bacillus Calmette\u2013Gu\u00e9rin? Int J Urol. 2020;27(1):72\u201374.","DOI":"10.1111\/iju.14139"},{"key":"152356","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1111\/iju.14139","DOI":"10.1111\/iju.14139"},{"key":"152357","doi-asserted-by":"crossref","unstructured":"Herr HW. Intravesical Bacille Calmette-Gu\u00e9rin in patients with asymptomatic bacteriuria. JAMA. 2011;305(14):1413\u20131414.","DOI":"10.1001\/jama.2011.428"},{"key":"152358","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1001\/jama.2011.428","DOI":"10.1001\/jama.2011.428"},{"key":"152359","doi-asserted-by":"crossref","unstructured":"Herr HW. Cystoscopy and intravesical bacille Calmette\u2013Gu\u00e9rin therapy in antibiotic-na\u00efve patients with bladder cancer with asymptomatic bacteriuria: an update. Arab J Urol. 2016;14(2):75\u201377.","DOI":"10.1016\/j.aju.2016.03.002"},{"key":"152360","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.aju.2016.03.002","DOI":"10.1016\/j.aju.2016.03.002"},{"key":"152361","doi-asserted-by":"crossref","unstructured":"Brausi M, Oddens J, Sylvester R, et al. Side effects of Bacillus Calmette-Gu\u00e9rin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC Genito-Urinary Cancers Group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol. 2014;65(1):69\u201376.","DOI":"10.1016\/j.eururo.2013.07.021"},{"key":"152362","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2013.07.021","DOI":"10.1016\/j.eururo.2013.07.021"},{"key":"152363","doi-asserted-by":"crossref","unstructured":"van der Meijden APM, Sylvester RJ, Oosterlinck W, et al. Maintenance Bacillus Calmette-Guerin for Ta T1 bladder tumors is not associated with increased toxicity: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III trial. Eur Urol. 2003;44(4):429\u2013434.","DOI":"10.1016\/S0302-2838(03)00357-9"},{"key":"152364","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/S0302-2838(03)00357-9","DOI":"10.1016\/S0302-2838(03)00357-9"},{"key":"152365","doi-asserted-by":"crossref","unstructured":"Nummi A, J\u00e4rvinen R, Sairanen J, et al. A retrospective study on tolerability and complications of bacillus Calmette-Gu\u00e9rin (BCG) instillations for non-muscle-invasive bladder cancer. Scand J Urol. 2019;53(2\u20133):116\u2013122.","DOI":"10.1080\/21681805.2019.1609080"},{"key":"152366","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1080\/21681805.2019.1609080","DOI":"10.1080\/21681805.2019.1609080"},{"key":"152367","doi-asserted-by":"crossref","unstructured":"Nummi A, Nurminen P, J\u00e4rvinen R, et al. Time to abandon routine urine screening prior bacillus Calmette-Gu\u00e9rin administration in asymptomatic patients. BJUI Compass. 2025;6(12):e70117.","DOI":"10.1002\/bco2.70117"},{"key":"152368","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1002\/bco2.70117","DOI":"10.1002\/bco2.70117"},{"key":"152369","doi-asserted-by":"crossref","unstructured":"Herr HW. Intravesical Bacillus Calmette-Gu\u00e9rin outcomes in patients with bladder cancer and asymptomatic bacteriuria. J Urol. 2012;187(2):435\u2013437.","DOI":"10.1016\/j.juro.2011.10.032"},{"key":"152370","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.juro.2011.10.032","DOI":"10.1016\/j.juro.2011.10.032"},{"key":"152371","doi-asserted-by":"crossref","unstructured":"Nurminen P, Nummi A, Kesti O, et al. Comparison of Bacillus Calmette-Gu\u00e9rin maintenance therapy with monthly instillations and the Southwest Oncology Group Protocol in the treatment of non-muscle-invasive bladder cancer. Eur Urol Focus. 2023;9(6):1000\u20131007.","DOI":"10.1016\/j.euf.2023.04.012"},{"key":"152372","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.euf.2023.04.012","DOI":"10.1016\/j.euf.2023.04.012"},{"key":"152373","doi-asserted-by":"crossref","unstructured":"Herr HW. Intravesical Bacille Calmette-Gu\u00e9rin eradicates bacteriuria in antibiotic-na\u00efve bladder cancer patients. Eur Urol. 2013;63(5):832\u2013835.","DOI":"10.1016\/j.eururo.2012.08.013"},{"key":"152374","doi-asserted-by":"crossref","unstructured":"https:\/\/doi.org\/10.1016\/j.eururo.2012.08.013","DOI":"10.1016\/j.eururo.2012.08.013"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45539\/53651","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/45539\/53651","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T08:34:29Z","timestamp":1777019669000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/45539"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,24]]},"references-count":32,"URL":"https:\/\/doi.org\/10.2340\/sju.v61.45539","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,24]]}}}